Phase 3 trial of solengepras for Parkinson’s disease now fully enrolled
WHY IT MATTERS
If solengepras proves effective in this Phase 3 trial, it could offer Parkinson's patients a new treatment option that works through a different mechanism than current dopamine-based therapies, potentially helping those with motor fluctuations who don't respond adequately to standard medications alone.
A large clinical trial testing a new Parkinson's disease medication called solengepras has finished enrolling 341 patients. This medication works differently than standard Parkinson's drugs and is being tested alongside regular treatments to see if it helps patients who experience movement problems that come and go throughout the day.
Enrollment is now complete in a Phase 3 trial assessing the safety and efficacy of solengepras (CVN424), Cerevance’s experimental non-dopaminergic therapy, in people with Parkinson’s disease. The Phase 3 ARISE trial (NCT06553027) is assessing solengepras’ efficacy, when given with levodopa and other standard Parkinson’s medications, in 341 patients with motor fluctuations who have an average of three […] The post Phase 3 trial of solengepras for Parkinson’s disease now fully enrolled